Lower GI 2017

Statement – CRT and Oxaliplatin?

• The rationale to add oxaliplatin (and other concurrent systemic agents) to CRT for rectal cancer is not primarily for radiosensitization, pCR, or even local control ( – unless organ preservation is attempted ).

• The most important objective is to improve DFS/OS